However, whether T cell responses to these additional antigens are due to tumor antigen release in the immunogenic context of MRB-driven oncolysis, as we have observed previously when employing an oncolytic vaccinia virus expressing a CXCR4 antagonist [63], or through direct tumor attack by prime/boost vaccine-elicited T cells is unclear. This evidence concerns the gene CXCR4 and neoplasm.